✦ LIBER ✦

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

✍ Scribed by Van Gaal, Luc; Souhami, Elisabeth; Zhou, Tianyue; Aronson, Ronnie

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Efficacy and safety of the dipeptidyl pe

✍ K. Hermansen; M. Kipnes; E. Luo; D. Fanurik; H. Khatami; P. Stein; Sitagliptin S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

Glycaemic efficacy of glucagon-like pept

✍ C. F. Deacon; E. Mannucci; B. Ahrén 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

Pharmacokinetics, safety, and efficacy o

✍ Giorda, Carlo B.; Nada, Elisa; Tartaglino, Barbara 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 336 KB

Erratum to: Pharmacokinetics, safety, an

✍ Giorda, Carlo B.; Nada, Elisa; Tartaglino, Barbara 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 154 KB